|
Oncology
In the field of oncology, Autoimmune has already developed many
anti-cancer botanical extracts. Unlike chemotherapy, Autoimmune's
method of treatment is not to attack the normal cells. Chemotherapy
poisons not only the cancer cells but also other normal cells of
the body, resulting in many side effects. In order to achieve effective
killing of cancer cells and shrinking of tumour with minimized side
effects, Autoimmune's approach uses only water-based compounds to
selectively fight cancer cells and to equip our body's natural immune
system to help overpower cancer cells effectively.
In
our quest to set new standards in safety and effectiveness with
our formulations, Autoimmune has engaged Universiti Putra Malaysia
(UPM) to verify in vitro anticancer activities of 35 of
Autoimmune's botanical based formulations against a panel of human
cancer cell lines including lung cancer, prostate cancer and breast
cancer. In vitro anticancer potential of the extracts
have been confirmed and Autoimmune has identified the most potent
extract beneficial for breast cancer treatment. A reputable foreign
laboratory has recently performed in vivo xenograft studies
and confirmed anti-breast tumour activities and tumour growth inhibition
properties of ASB001
with no signs of toxicity.
-
ASB001
In
the first batch of extracts to be tested by UPM, all nine of Autoimmune's
extracts have yielded in vitro anti-cancer activities.
However, extract ASB001 stands out as the most potent and effective
extract to be beneficial for breast cancer treatment. It has been
shown to kill cancer cells and slow down cell replication and
is especially selective towards breast cancer cells.
ASB001
was tested on mice and exhibited no toxicity. This is based on
results that showed no reduction in the body weight at the recommended
therapeutic dosage. This therefore suggests few adverse side effects.
The tests on animals
(SCID mice)
done abroad confirmed the superiority
of this extract
as ASB001 at 300mg/kg administered daily by oral gavage (PO) did not observe any signs of over toxicity after dosing, and no significant changes were observed in body weight throughout the experimental period.
Like our other extracts, ASB001 is also water-based.
Viral/Infectious Diseases
In
2002, the IMR conducted a pilot trial to assess the safety and efficacy
of Autoimmune's formulation on terminally ill AIDS patients. The result
indicates proven effectiveness of Autoimmune's formulation with viral
loads being significantly reduced with no reported adverse reactions
although patients' immune systems were at a substantially weakened
state. These results were announced to the media by the Minister of
Health. Confirmation of this anti-viral activity can be viewed at
NINPVB's website: www.ninpv.org/press.htm
and National Committee for Research and Development in Herbal Medicine's
website: www.nrdhm.org/press2.asp.
- HEPAT™
UPM has been appointed to conduct in vivo studies on
HEPAT™ to evaluate its antihepatotoxicity (hepatoprotective
/ liver protective) properties. A pilot trial with
a local medical centre
to evaluate HEPAT™'s safety
and efficacy on patients with elevated liver enzymes and Hepatitis
B patients is expected to commence soon.
- ASB010
Autoimmune has engaged Universiti Malaya (UM) to evaluate and
verify in vitro anti-viral activities of our ASB010 extract
against dengue virus. The tests have yielded substantial antiviral
activity. Autoimmune is planning to conduct a pilot trial to assess
the safety and efficacy of ASB010 as an anti-viral against the
dengue virus.
Cardiovascular/Lifestyle
Diseases
Autoimmune recognizes the medical need for a safe and effective treatment
for patients suffering from cardiovascular diseases without causing side effects
or toxicity to the liver or kidney .
- KHOLESCAIR™
UM has conducted an investigation to evaluate the effects of KHOLESCAIR™
on vascular endothelial function in the isolated diabetic rat
aorta. In vivo studies have shown that it significantly enhanced
the relaxation responses and improved the sensitivity of diabetic
aortas as well as inhibit free radicals. It has also been shown
to significantly improve vascular endothelial function. The studies
have shown significant enhanced relaxation responses, reversal
of endothelial cell dysfunction in diabetic rat aortas as well
as acting as a potent free radical scavenger (antioxidant). It
has also been shown to modulate blood vessel function in diabetes
in animal studies.
The
investigation on cardiovascular protective effects of KHOLESCAIR™
in experimental hypertension evaluating its effects on various
cardiovascular parameters have led to a significant reduction
in the systolic blood pressure in hypertensive rats, significant
reduction in aortic wall thickness and significant prevention in the
development of smooth muscle hypertrophy. The results demonstrated
that chronic administration of KHOLESCAIR™ improves vascular
function in hypertensive rats. A pilot trial will later follow
to assess its safety and efficacy to treat hypertension, to reverse endothelial dysfunction and also to reverse atherosclerosis (not only to reduce progression of coronary atherosclerosis but also to prevent it and cause regression).
|
